EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib
Z Ezzoukhry, C Louandre, E Trécherel… - … journal of cancer, 2012 - Wiley Online Library
Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …
Molecular mechanism and prediction of sorafenib chemoresistance in human hepatocellular carcinoma
N Nishida, M Kitano, T Sakurai, M Kudo - Digestive Diseases, 2015 - karger.com
Hepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide,
and prognosis remains unsatisfactory when the disease is diagnosed at an advanced stage …
and prognosis remains unsatisfactory when the disease is diagnosed at an advanced stage …
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma
J Chen, R Jin, J Zhao, J Liu, H Ying, H Yan, S Zhou… - Cancer letters, 2015 - Elsevier
Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …
New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma
A Galmiche, B Chauffert, JC Barbare - Cancer letters, 2014 - Elsevier
Sorafenib, an orally-available kinase inhibitor, is the only medical treatment with a proven
efficacy against Hepatocellular Carcinoma (HCC). Although the overall clinical efficacy of …
efficacy against Hepatocellular Carcinoma (HCC). Although the overall clinical efficacy of …
[HTML][HTML] Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma
B Zhai, XY Sun - World journal of hepatology, 2013 - ncbi.nlm.nih.gov
Sorafenib, the unique drug as first-line treatment for advanced hepatocellular carcinoma
(HCC), has opened a window of hope after searching for effective agents to combat HCC for …
(HCC), has opened a window of hope after searching for effective agents to combat HCC for …
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth
H van Malenstein, J Dekervel, C Verslype… - Cancer letters, 2013 - Elsevier
Sorafenib leads to a survival benefit in patients with advanced hepatocellular carcinoma but
its use is hampered by the occurrence of drug resistance. To investigate the molecular …
its use is hampered by the occurrence of drug resistance. To investigate the molecular …
The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
W Tang, Z Chen, W Zhang, Y Cheng, B Zhang… - Signal transduction and …, 2020 - nature.com
Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
MJ Blivet-Van Eggelpoël, H Chettouh, L Fartoux… - Journal of …, 2012 - Elsevier
BACKGROUND & AIMS: Sorafenib is the standard of care for the treatment of advanced
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …
New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies
L Niu, L Liu, S Yang, J Ren, PBS Lai… - Biochimica et Biophysica …, 2017 - Elsevier
It is disappointing that only a few patients with hepatocellular carcinoma (HCC) obtain a
significant survival benefit from the sorafenib treatment, which is currently regarded as a first …
significant survival benefit from the sorafenib treatment, which is currently regarded as a first …
[HTML][HTML] Inhibition of the PI3K/Akt signaling pathway reverses sorafenib‑derived chemo‑resistance in hepatocellular carcinoma
H Zhang, Q Wang, J Liu, H Cao - Oncology Letters, 2018 - spandidos-publications.com
Long‑term sorafenib treatment triggers resistance to chemotherapy in patients with
hepatocellular carcinoma (HCC). In order to investigate the mechanisms of sorafenib …
hepatocellular carcinoma (HCC). In order to investigate the mechanisms of sorafenib …